Leo will more likely sell the rights for Brilacidin for use on covid19 at $10B+ if trials work out well and take the money to further develop Brilacidin in other applications along with Kevetrin.
Leo will more likely sell the rights for Brilacidin for use on covid19 at $10B+ if trials work out well and take the money to further develop Brilacidin in other applications along with Kevetrin.